BioCentury | Jun 26, 2020
Product Development

21st century pandemic, prehistoric clinical trials

...was over. This was the case during the 2009 swine flu pandemic. At the time, peramivir...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...tumors have EGFR mutations BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) / CSL Ltd. (ASX:CSL) EC approves Alpivab peramivir...
BioCentury | May 4, 2018
Clinical News

EC approves BioCryst's Alpivab for influenza

...BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said the European Commission approved an MAA for Alpivab peramivir to treat...
...The Seqirus unit of CSL Ltd. (ASX:CSL) has exclusive, worldwide rights from BioCryst to commercialize peramivir...
...N.C. Product: Rapivab peramivir (Alpivab - EU, Rapiacta - Japan, PeramiFlu - South Korea) (BCX-1812, RWJ-270201...
BioCentury | May 1, 2018
Company News

EC approves BioCryst's Alpivab for influenza

...BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said the European Commission approved an MAA for Alpivab peramivir to treat...
...The Seqirus unit of CSL Ltd. (ASX:CSL) has exclusive, worldwide rights from BioCryst to commercialize peramivir...
BioCentury | Mar 1, 2018
Clinical News

CHMP backs approval of BioCryst's Alpivab

...U.S. as Rapivab. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX), Durham, N.C. Product: Rapivab peramivir (Alpivab - EU, Rapiacta...
...N.C. Product: Rapivab peramivir (Alpivab - EU, Rapiacta - Japan, PeramiFlu - South Korea) (BCX-1812, RWJ-270201...
...peramivir (Alpivab - EU, Rapiacta - Japan, PeramiFlu - South Korea) (BCX-1812, RWJ-270201) Business: Infectious Sandi Wong Alpivab Peramivir BioCryst...
BioCentury | Feb 24, 2018
Company News

CHMP backs approval of Mylotarg, Alpivab, Kineret

...CHMP announced a spate of opinions Friday, including positive recommendations for Mylotarg gemtuzumab ozogamicin, Alpivab peramivir...
...mAb against CD33 linked to the calicheamicin cytotoxin (see BioCentury Extra, Sept. 1, 2017) . Alpivab...
...uncomplicated influenza. The injectable formulation of viral neuraminidase inhibitor is approved in the U.S. as Rapivab...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...Interim Ph III PROSPECT data Mid-2017 BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) / CSL Ltd. (ASX:CSL) Rapivab peramivir...
BioCentury | Jun 15, 2017
Clinical News

FDA accepts BioCryst's sNDA for Rapivab in pediatric patients

...Product: Rapivab peramivir ( Alpivab - EU, Rapiacta - Japan, PeramiFlu - South Korea) ( BCX-1812...
...peramivir ( Alpivab - EU, Rapiacta - Japan, PeramiFlu - South Korea) ( BCX-1812 , RWJ-270201...
...EU, Rapiacta - Japan, PeramiFlu - South Korea) ( BCX-1812 , RWJ-270201) Business: Infectious Julian Zhu BCX-1812 PeramiFlu Peramivir Rapiacta Rapivab RWJ-270201 BioCryst...
BioCentury | Mar 10, 2017
Financial News

BioCryst raises $45M in follow-on

...is in Phase II testing to treat hereditary angioedema (HAE). The company also markets Rapivab peramivir...
...to treat influenza infection. The injectable formulation of viral neuraminidase inhibitor is under EMA review. Chris Lieu BCX7353 Rapivab BioCryst...
Items per page:
1 - 10 of 164